Protalix BioTherapeutics, Inc.

PLX

Exchange: NYSE
Industry: Biological Products, (No Diagnostic Substances)
SEC CIK: 0001006281

SEC filings (opens in a new tab)

No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Protalix BioTherapeutics, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024 All holders in Q1 2024

13F holders of PLX: Q1 2024 compared with Q2 2024
Measure	Q1 2024	Of which not filed for Q2 2024	Q2 2024	Change
Holders	64	1	66	+3
Shares	9.39M	610	5.64M	−3.75M (−39.9%)
Value	$11.9M	$769	$6.60M	−$5.32M (−44.6%)

1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (26)

Institutions that held Protalix BioTherapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to PLX in Q2 2024
Institution	Shares	Value	% of portfolio
Y-Intercept (Hong Kong) Ltd	158,259	$185.2K	0.01%
Centiva Capital, LP	130,332	$152.5K	0.01%
Qube Research & Technologies Ltd	121,030	$141.6K	0.00%
HRT Financial LP	80,224	$93.0K	0.00%
Paloma Partners Management Co	79,442	$92.9K	0.01%
Point72 Asia (Singapore) Pte. Ltd.	68,163	$79.8K	0.02%
Ground Swell Capital, LLC	62,234	$72.8K	0.07%
AQR Capital Management LLC	57,106	$66.8K	0.00%
Mirae Asset Global ETFs Holdings Ltd.	34,167	$40.0K	0.00%
Cubist Systematic Strategies, LLC	32,031	$37.5K	0.00%
Schonfeld Strategic Advisors LLC	27,900	$32.6K	0.00%
Ethic Inc.	20,039	$23.4K	0.00%
Jump Financial, LLC	14,224	$16.6K	0.00%
Balyasny Asset Management LLC	13,299	$15.6K	0.00%
Savant Capital, LLC	11,996	$14.0K	0.00%
Cascade Financial Partners, LLC	11,100	$13.0K	0.00%
Ellevest, Inc.	10,494	$12.3K	0.00%
Catalyst Funds Management Pty Ltd	10,200	$11.9K	0.00%
Macquarie Group Ltd	3,460	$4.05K	0.00%
The PNC Financial Services Group, Inc.	1,418	$1.66K	0.00%
Russell Investments Group, Ltd.	519	$607	0.00%
Nisa Investment Advisors, LLC	342	$400	0.00%
Activest Wealth Management	300	$351	0.00%
Y.D. More Investments Ltd	220	$257	0.00%
Farther Finance Advisors, LLC	85	$99	0.00%
SRS Capital Advisors, Inc.	39	$46	0.00%

Sold out (23)

Institutions that held Protalix BioTherapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.

Institutions that sold out of PLX in Q2 2024
Institution	Shares, Q1 2024	Value, Q1 2024
State Street Corp	826,581	$1.04M
Geode Capital Management, LLC	754,110	$950.2K
Vanguard Group Inc	330,047	$415.9K
Nuveen Asset Management, LLC	271,795	$342.5K
Bank of New York Mellon Corp	173,206	$218.2K
Virtu Financial LLC	157,516	$198.0K
Charles Schwab Investment Management Inc	153,561	$193.5K
American International Group, Inc.	33,321	$42.0K
Voya Investment Management LLC	27,023	$34.0K
Invesco Ltd.	25,908	$32.6K
Verition Fund Management LLC	23,465	$29.6K
Alliancebernstein L.P.	23,400	$29.5K
Wells Fargo & Company	23,369	$29.4K
SG Americas Securities, LLC	21,467	$27.0K
Price T Rowe Associates Inc	15,982	$21.0K
ProShare Advisors LLC	12,147	$15.3K
California State Teachers Retirement System	6,797	$8.56K
Legal & General Group Plc	5,359	$6.75K
Ameritas Investment Partners, Inc.	4,638	$5.84K
Truvestments Capital LLC	3,880	$4.89K
Amalgamated Bank	1,894	$2.00K
Natixis	100	$126
Nelson, Van Denburg & Campbell Wealth Management Group, LLC	9	$11

Not filed for Q2 2024 yet (1)

Institutions that held Protalix BioTherapeutics, Inc. at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding PLX in Q1 2024 that haven't filed for Q2 2024
Institution	Shares, Q1 2024	Value, Q1 2024
Highlander Capital Management, LLC	610	$769